CymaBay Presents Results On The Potential Of Seladelpar In Treatment Of Patients With Primary Biliary Cholangitis At ACG 2023
Portfolio Pulse from Happy Mohamed
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) presented findings from its post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis (PBC). The study showed that treatment with seladelpar is correlated with a significant decrease in both IL-31 levels and levels of patient-reported itch. The company also presented a post-hoc analysis of four seladelpar clinical trials from 2015 to 2022, which found that PBC patients previously treated with ursodeoxycholic acid (UDCA) with elevated alkaline phosphatase (ALP) who did not meet current clinical guidelines for second-line treatment, nevertheless had a significant risk of disease progression.
October 23, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the Phase 3 ENHANCE study of seladelpar for the treatment of PBC could potentially boost the stock price of CymaBay Therapeutics in the short term.
The positive results from the Phase 3 ENHANCE study of seladelpar for the treatment of PBC could potentially boost the stock price of CymaBay Therapeutics in the short term. This is because the results indicate that the company's drug has potential in treating PBC, a condition with limited treatment options. This could lead to increased sales and revenue for the company, which would likely be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100